Trial Profile
Efficacy of a selective MEK (trametinib) and BRAFV600E (dabrafenib) inhibitors associated with radioactive iodine (RAI) for the treatment of refractory metastatic differentiated thyroid cancer with RAS or BRAFV600E mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary) ; Iodine-131; Thyrotropin alfa
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms MERAIODE
- 19 Apr 2023 Results assessing the efficacy and safety of dabrafenib-trametinib-131I for the treatment of radioactive iodine refractory metastatic differentiated thyroid cancer (DTC) with a BRAFp.V600E mutation, published in the Clinical Cancer Research.
- 03 Jun 2022 Status changed from active, no longer recruiting to completed.
- 27 Sep 2021 Planned primary completion date changed from 1 Dec 2022 to 18 Nov 2021.